跳至主要内容
临床试验/CTRI/2021/11/037864
CTRI/2021/11/037864招募中未知

A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE EFFICACY OF ORAL TACROLIMUS WITH ORAL MYCOPHENOLATE MOFETIL IN PATIENTS WITH SYSTEMIC SCLEROSIS - INTERSTITIAL LUNG DISEASE - INSIST

PGIMER Chandigarh0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. 1. Age 18-75 years
  • 2. Patients with SSc as diagnosed by the American College of
  • Rheumatology (ACR) criteria, 2013 and patients with other connective tissue diseases who, in parallel, meet the ACR criteria for SSc (overlap syndromes except inflammatory myopathy)
  • 3. Duration of SSc for ââ?°Â¤7 years, with onset defined as the appearance of the first non-Raynaudââ?¬•s symptom
  • 4. Consenting for participating in study
  • 5. FVC - 40-80%
  • 6. DLco- 30-80% of normal
  • 7. HRCT chest suggestive of ILD ( >10% of lung parenchyma)
  • 8. May have received immunosuppression CYC (ââ?°Â¥6 doses of IV or oral for 6 months) or MMF (ââ?°Â¥6months) previously but at least >6 months prior to randomization, and still have progressive declining lung function indicated by change of 10% in FVC and 15% in DLCO
  • 9. On maintenance immunosuppression with azathioprine, low dose steroids (ââ?°Â¤10mg/day), but having progressive declining lung function

排除标准

  • 1. FVC <40%
  • 2. DLco <30%
  • 3. Serum creatinine ââ?°Â¥1.2mg/dl
  • 4. Smoking tobacco in last 6 months
  • 5. Clinically significant abnormality on chest-x-ray other than ILD (e.g- lung mass, effusion)
  • 6. Immunosuppression- MMF or cyclophosphamide in last 30 days
  • 7. Prednisolone ââ?°Â¥10mg/day
  • 8. Persistent leucopenia( <4000/mm3) or thrombocytopenia ( <100,000/mm3)
  • 9. Pregnant or breastfeeding females
  • 10. Severe pulmonary arterial hypertension (mean pulmonary arterial pressure >55mmHg) requiring drug therapy
  • 11. Significant airflow obstruction (pre-bronchodilator FEV1/FVC ââ?°Â¤0.65%)
  • 12. Known hypersensitivity to the trial medication or its components
  • 13. Life expectancy of <3 years for disease other than the underlying CTD in investigator assessment
  • 14. Uncontrolled congestive heart failure
  • 15. Uncontrolled hypertension
  • 16. Major surgical procedures planned to occur during trial period
  • 17. Any other abnormalities noted on chest X-ray or HRCT other than ILD
  • 18. Active infection
  • 19. Active myositis
  • 20. Known seizure disorder
  • 21. Other serious co-morbidities which could compromise the patientââ?¬•s ability to complete the study
  • 22. Allergy/hypersensitivity to medication or its constituents

研究者

相似试验